Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs.
Curr Pharm Des
; 23(40): 6215-6222, 2017.
Article
in En
| MEDLINE
| ID: mdl-28641545
ABSTRACT
NO produced by eNOS plays important roles in the cardiovascular system. Alterations in eNOS activity and expression occur in various cardiovascular disorders and eNOS constitutes a therapeutic target. In addition to posttranslational modifications of eNOS that affect eNOS activity, transcriptional and post-transcriptional regulation of eNOS expression also controls eNOS-derived NO production. Bradykinin is an important determinant of vascular function and participates in the regulation of eNOS activity and expression. A number of currently used drugs or investigational molecules targeting specific ion channels, enzymes or receptors, including dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, statins, AT1 receptor blockers and angiotensin-(1-7), increase eNOS expression and activity. In this context, activation of bradykinin B2 receptors appears to be a common step for these drugs to promote eNOS expression, which certainly contributes to their therapeutic actions.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Bradykinin
/
Cardiovascular Agents
/
Nitric Oxide Synthase Type III
Limits:
Animals
/
Humans
Language:
En
Journal:
Curr Pharm Des
Journal subject:
FARMACIA
Year:
2017
Document type:
Article
Affiliation country:
France
Publication country:
AE
/
EMIRADOS ÁRABES UNIDOS
/
EMIRATOS ARABES UNIDOS
/
UNITED ARAB EMIRATES